Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.52 |
| ▸ | PPARA | Q07869 | 10/20 | 0.52 |
| ▸ | ECE1 | P42892 | 5/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400397 | 1.00 | PPARG (0.52) | PPARGPPARAECE1MMEACE | |
| SCHEMBL1400250 | 0.89 | PPARA (0.62) | PPARGPPARA | |
| SCHEMBL1400670 | 0.89 | PPARA (0.62) | PPARGPPARA | |
| SCHEMBL1400312 | 0.89 | PPARA (0.62) | PPARGPPARA | |
| SCHEMBL6226923 | 0.89 | PPARA (0.62) | PPARGPPARA | |
| SCHEMBL821077 | 0.89 | PPARA (0.62) | PPARGPPARA | |
| SCHEMBL1400682 | 0.86 | ESR1 (0.57) | PPARGPPARAECE1NQO2MTNR1A | |
| SCHEMBL821080 | 0.86 | ESR1 (0.57) | PPARGPPARAECE1NQO2MTNR1A | |
| SCHEMBL820653 | 0.83 | MTNR1A (0.48) | PPARGPPARANQO2MTNR1AMTNR1B | |
| SCHEMBL13355771 | 0.83 | MTNR1A (0.48) | PPARGPPARANQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1435951-B1 | PHENYL SUBSTITUTED 5-MEMBERED NITROGEN CONTAINING HETEROCYCLES FOR THE TRETMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6828335-B2 | Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis | BAYER PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| EP-1435951-A1 | PHENYL SUBSTITUTED 5-MEMBERED NITROGEN CONTAINING HETEROCYCLES FOR THE TRETMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1414809-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004011446-A1 | INDANE, DIHYDROBENZOFURAN, AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC | 2003-11-20 | — | — | US | disclosed |
| WO-2003037332-A1 | PHENYL SUBSTITUTED 5-MEMBERED NITROGEN CONTAINING HETEROCYCLES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | ACHE, CHAT, APP | PPARG 684/4885PPARA 368/4885ECE1 1473/4885 |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARG 578/4885PPARA 365/4885ECE1 773/4885 |
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | GPR119, EGLN3, PC | PPARG 13/4885PPARA 49/4885ECE1 1430/4885 |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, AANAT | PPARG 596/4885PPARA 507/4885ECE1 1861/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PPARG 988/4885PPARA 534/4885ECE1 865/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PPARG 621/4885PPARA 516/4885ECE1 1949/4885 |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARG 578/4885PPARA 365/4885ECE1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.